Get the Stockscreener App
1.30
1.56%
0.02
After Hours:
1.31
0.01
+0.77%
Vivani Medical Inc stock is traded at $1.30, with a volume of 134.13K.
It is up +1.56% in the last 24 hours and up +8.33% over the past month.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
See More
Previous Close:
$1.28
Open:
$1.3
24h Volume:
134.13K
Relative Volume:
0.29
Market Cap:
$112.11M
Revenue:
-
Net Income/Loss:
$-27.09M
P/E Ratio:
-3.221
EPS:
-0.4036
Net Cash Flow:
$-26.52M
1W Performance:
-3.70%
1M Performance:
+8.33%
6M Performance:
-5.80%
1Y Performance:
-19.25%
1-Day Range:
$1.2601
$1.315
1-Week Range:
$1.25
$1.475
52-Week Range:
$0.9228
$1.92
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
415-506-8462
Address
1350 S. LOOP ROAD, ALAMEDA
Compare VANI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.30 | 110.38M | 0 | -27.09M | -26.52M | -0.4036 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vivani Medical Inc Stock (VANI) Latest News
Vivani Medical Market Sentiment - Benzinga España
Vivani Medical Inc. Revenue Breakdown – FWB:U5P - TradingView
Vivani Medical Inc (VANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - bernama
VANI|Vivani Medical Inc|Price:1.300|Chg%:+0.020 - TradingKey
Vivani Medical Inc (VANI) Cash Flow - TradingKey
Vivani Medical Inc (VANI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VANI|Vivani Medical Inc|Price:1.280|Chg%:-0.110 - TradingKey
Enterprise value to revenue forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Enterprise value to revenue forward of Vivani Medical Inc. – FWB:U5P - TradingView
Enterprise value to EBITDA forward of Vivani Medical Inc. – FWB:U5P - TradingView
ClearOne (CLRO) to acquire Cortigent, cede control to Vivani in stock deal - Stock Titan
Vivani Medical Highlights Upcoming SLIM-1 First Dosing Milestone - TipRanks
Form 4 Vivani Medical Inc For: 16 July By Investing.com - Investing.com Nigeria
Vivani Medical (NASDAQ: VANI) Targets August Human Trial For Semaglutide Implant Following Novo Nordisk Evaluation Deal - foreignpolicyjournal.com
New Form 4! Biggun at that! Hehehe - Moomoo
Vivani Medical director Gregg Williams buys $1m in stock - Investing.com UK
Vivani Medical director Gregg Williams buys $1m in stock By Investing.com - Investing.com Australia
Vivani Medical (NASDAQ: VANI) insider buys 793,650 shares at $1.26 - Stock Titan
Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation - TradingView
Vivani Medical director, 10% owner Gregg Williams reports purchase of USD 999,999 common shares - Bitget
Vivani Medical at emerging growth conference: implant push gains traction By Investing.com - Investing.com South Africa
Vivani Medical (VANI) Emerging Growth Conference Summary - Quartr
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal - MarketBeat
Vivani Medical at emerging growth conference: implant push gains traction - Investing.com
Vivani Medical (VANI) Edges Lower in Light Trading as Support Level Comes into FocusBreakout Trade - dars.gov.et
Vivani Medical to present its GLP-1 drug implan... - Pluang
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026 - The Manila Times
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream - GlobeNewswire Inc.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss - CNBC
Vivani Medical Inc. (NASDAQ: VANI) Share Price, VANI Stock News, VANI Share Price & Updates - Kalkine
H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal - Investing.com UK
H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com - Investing.com South Africa
Analysts Set Expectations for Vivani Medical Q1 Earnings - MarketBeat
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $3.5 - Moomoo
Vivani Medical Inc. (VANI) Q1 2026 Earnings: EPS Beat Bolsters Investor SentimentReturn On Capital - dars.gov.et
VANI Q1 2026 Earnings: Narrower Loss Surprise Powers 18.5% Stock JumpEarnings Revision Upgrade - dars.gov.et
Vivani Medical (VANI) Receives a Buy from Lake Street - The Globe and Mail
Vivani Advances GLP-1 Implant Program With Novo Nordisk - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
ClearOne (CLRO) surges 48% as float turns over on Cortigent merger math - TechStock²
Vivani Flat on Hookup with Novo - Baystreet.ca
Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Sector Update: Healthcare - Moomoo
Vivani Medical Partners with Novo Nordisk to Evaluate Ultra Long-Acting Semaglutide Implant for Weight Management - Minichart
Vivani in pact with Novo to study Wegovy implant (NVO:NYSE) - Seeking Alpha
Novo Nordisk to evaluate Vivani Medical's semaglutide implant - marketscreener.com
Vivani Medical Says Novo Nordisk to Evaluate Semaglutide Implant for Weight Management - marketscreener.com
Vivani Medical to Merge Cortigent Into ClearOne; Receives 12.5M Shares, Deal Needs $10–15M Financing - TradingView
Vivani Medical Enters into Agreement with Novo Nordisk… - aapnews.aap.com.au
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):